First Responders-Comprehensive Addiction and Recovery Act
Short Title:
FR-CARA
Initial Announcement
Back to the Grants Dashboard
Notice of Funding Opportunity (NOFO)
NOFO Number: TI-25-001
Posted on Grants.gov: Friday, June 27, 2025
Application Due Date: Tuesday, July 22, 2025
Catalog of Federal Domestic Assistance (CFDA) Number: 93.243
Intergovernmental Review (E.O. 12372): Applicants must comply with E.O. 12372 if their state(s) participates. Review process recommendations from the State Single Point of Contact (SPOC) are due no later than 60 days after application deadline.
Public Health System Impact Statement (PHSIS) / Single State Agency Coordination: Applicants must send the PHSIS to appropriate State and local health agencies by application deadline. Comments from Single State Agency are due no later than 60 days after application deadline.
Description
The purpose of the FR-CARA program is to train first responders and communities in administering and distributing opioid overdose reversal medications. Recipients are expected to provide overdose prevention training and education, engage with their communities and partners, and implement activities aligned with evidence-based, trauma-informed care practices.
Eligibility
Eligibility for this program is statutorily limited to states, local governmental entities, and American Indian/Alaska Native (AI/AN) tribes and tribal organizations.
Award Information
Funding Mechanism: Grant
Anticipated Total Available Funding: Up to $10,000,000
Anticipated Number of Awards: 12-33 awards
Anticipated Award Amount: $300,000–$800,000 per year
Length of Project: Up to 4 years
Cost Sharing/Match Required?: No
Proposed budgets cannot exceed $300,000-$800,000 in total costs (direct and indirect) in any year of the proposed project. Annual continuation awards will depend on the availability of funds, grantee progress in meeting project goals and objectives, timely submission of required data and reports, and compliance with all terms and conditions of award.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
